Ryan Cross
@scienceboss.bsky.social
đ€ 61
đ„ 20
đ 115
Senior Science Correspondent at Endpoints News. Reach out privately on Signal: RyanCross.25
@generatebiomed.bsky.social
, one of the biggest companies dedicated to making protein therapies with AI, has filed for an IPO.
@andrewedunn.bsky.social
and I tackled the S-1 last night and pulled out some interesting details for our story in
@endpts.com
:
endpoints.news/flagships-ge...
loading . . .
Flagshipâs Generate files for an IPO in key test for the AI bio field
Generate Biomedicines files for IPO 9 days after starting Phase 3 trial of GB-0895 for severe asthma, with Flagship Pioneering owning 56.6% of AI-focused biotech company.
https://endpoints.news/flagships-generatebiomedicines-files-for-ipo-pitching-ai-driven-drugs/
5 days ago
0
1
1
My latest for
@endpts.com
: Chinese
#CRISPR
startup AccurEdit has raised $75 million for gene editing therapies. It has data in ATTR comparable to Intellia, data in PCSK9 comparable or slightly better than Verve, and is working on a novel therapy for MASH/NASH.
endpoints.news/china-startu...
loading . . .
China startup AccurEdit raises $75M for gene editing therapies showing early promise
AccurEdit Therapeutics raises $75M Series A for CRISPR medicines, reports promising data in ATTR and PCSK9 programs. CEO Yongzhong Wang leads development of gene therapies in China.
https://endpoints.news/china-startup-accuredit-raises-75m-for-gene-editing-therapies/
7 days ago
0
3
0
Lilly is partnering with Seamless Therapeutics on a gene editing therapy based not on CRISPR but enzymes called recombinases. It's big news for the post-CRISPR wave of startups making tools for precise gene insertion. My story in
@endpts.com
has the details:
endpoints.news/lilly-partne...
loading . . .
Lilly partners with startup developing recombinase-based gene editing
Seamless Therapeutics partners with Eli Lilly in $1.12B deal to develop recombinase-based gene editing for hearing loss, marking first big pharma deal for recombinase tech.
https://endpoints.news/lilly-partners-with-startup-developing-recombinase-based-gene-editing/
13 days ago
0
4
1
Harvard biologist
@davidsinclairphd.bsky.social
's startup
@lifebiosciences.bsky.social
is about to begin a clinical study of its gene therapy for "partial epigenetic reprogramming." It's a big first in the longevity field. I've got the details for
@endpts.com
-
endpoints.news/exclusive-fd...
loading . . .
Exclusive: In major test for longevity field, FDA greenlights study on a 'near total reset' of cells
Life Biosciences gets FDA approval to test aging reversal gene therapy in vision loss patients, using proteins discovered in David Sinclair's Harvard lab.
https://endpoints.news/exclusive-fda-greenlights-gene-therapy-study-to-rewind-the-age-of-cells/
14 days ago
0
3
1
Scribe Therapeutics, a
#CRISPR
gene editing company cofounded by Jennifer Doudna in 2017, plans to start its first clinical trial this summer. The startup's lead program is an epigenetic editor targeting PCSK9 to lower cholesterol. More details in
@endpts.com
:
endpoints.news/scribe-thera...
loading . . .
Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy
The companyâs lead program is an epigenetic silencing therapy designed to turn off genes without altering the underlying genetic code.
https://endpoints.news/scribe-therapeutics-plans-to-test-cholesterol-lowering-therapy-this-summer/
27 days ago
0
2
1
Former Tome Bio leader John Finn is continuing his search for the ideal gene insertion tool at Basecamp Research. Today, the startup revealed its first AI-generated enzymes (large serine recombinases) that can insert genes without CRISPR. More in
@endpts.com
:
endpoints.news/nvidia-partn...
loading . . .
Nvidia-partnered startup reveals AI-generated enzymes for precise gene insertion
Scientists at Basecamp Research say they have used âevolutionary AI models,â developed with help from chipmaker NVIDIA, to create a powerful new gene editing tool that can insert a new healthy gene in...
https://endpoints.news/nvidia-partnered-startup-reveals-ai-generated-enzymes-for-precise-gene-insertion/
29 days ago
1
2
2
Mirador Therapeutics has raised a $250M series B, bringing its total funding to more than $650M. The startup plans to have at least 10 clinical trial readouts of immunology drugs by the end of 2027. More details in my exclusive for
@endpts.com
: -
endpoints.news/mirador-rais...
loading . . .
Exclusive: Secretive startup Mirador raises $250M, plans to become immunology powerhouse
Mirador Therapeutics raises $250M Series B, eyes IPO. CEO Mark McKenna reveals clinical programs for Crohn's, IPF, RA and colitis, with 10+ data readouts expected by 2027.
https://endpoints.news/mirador-raises-250m-with-plans-to-become-an-immunology-powerhouse/
about 1 month ago
0
3
1
Gene editing pioneers Jennifer Doudna and
@urnov.bsky.social
have launched the first startup, Aurora Therapeutics (led by Ed Kaye), focused on making custom
#CRISPR
therapies that fix a patient's unique genetic mutation. My story for
@endpts.com
has the details:
endpoints.news/gene-editing...
loading . . .
Gene editing pioneers launch first startup focused on custom CRISPR therapies
Aurora Therapeutics launches with $16M to develop custom CRISPR cures, starting with PKU. Founded by Jennifer Doudna & Fyodor Urnov, led by Edward Kaye.
https://endpoints.news/gene-editing-pioneers-launch-first-startup-focused-on-custom-crispr-therapies/
about 1 month ago
1
2
0
Scoop: Rampart Bioscience, which launched with $125 million in Oct. 2023, has shut down. It's at least the fourth company to stop work on the very challenging task of creating non-viral gene therapies in recent years. More details in my story for
@endpts.com
:
endpoints.news/secretive-ra...
loading . . .
Secretive Rampart Bioscience shuts down after trying to crack non-viral gene therapy
Two former employees, who spoke under the condition of anonymity, confirmed that Rampart closed its doors last week after launching with $125 million.
https://endpoints.news/secretive-rampart-bioscience-closes-after-pursuing-non-viral-gene-therapy/
about 1 month ago
0
0
0
Itâs been a tumultuous couple of years for Vizgen and the broader spatial biology field. But with its 10X Genomics and Harvard litigation settled, Vizgen is looking to ramp up production and sales of its tools. Read more in my story for
@endpts.com
-
endpoints.news/vizgen-raise...
loading . . .
Vizgen raises $48M to propel push in spatial biology and multiomics tools
Vizgen raises $48M Series E to expand production of gene/protein mapping tools after settling litigation with 10X Genomics and Harvard, following merger with Ultivue.
https://endpoints.news/vizgen-raises-48m-for-push-in-spatial-biology-and-multiomics-tools/
about 1 month ago
0
0
0
Scoop: The well funded gene editing startup Tessera Therapeutics is cutting its headcount by 90 employees (about 35% of its workforce) just a month after landing a $150M partnership with Regeneron for its AATD therapy. Read more in my story for
@endpts.com
:
endpoints.news/tessera-ther...
loading . . .
Gene editing startup Tessera to lay off 90 employees, according to document, as it begins first clinical study
Tessera Therapeutics laying off 90 employees (35% of workforce) as it starts first clinical trial, affecting platform, R&D, sequencing & toxicology teams.
https://endpoints.news/tessera-therapeutics-to-lay-off-90-employees-according-to-document/
about 1 month ago
1
2
0
InduPro, a startup founded by former Merck scientists who invented MicroMappingâa way to identify protein interactionsâhas struck a partnership with Eli Lilly worth up to $950M to develop 3 bispecific or trispecific cancer drugs. More in my exclusive for
@endpts.com
:
endpoints.news/lilly-partne...
loading . . .
Exclusive: Lilly partners with protein mapping startup InduPro for up to $950M
InduPro Therapeutics partners with Eli Lilly on cancer drug development worth up to $950M, using MicroMapping tech to create bispecific antibodies, following recent Sanofi deal.
https://endpoints.news/lilly-partners-with-protein-mapping-startup-indupro-for-up-to-950m/
about 1 month ago
0
0
0
The gene editing toolbox has exploded since CRISPR was invented, with each new tool promising to be better than the last. Read my third deep and final deep dive of 2025 on the
#CRISPR
gene editing field's growing pains in
@endpts.com
endpoints.news/as-gene-edit...
loading . . .
Gene editing's search for a 'holy grail' has led to an explosion of tools, but few cures
Former Intellia scientist John Finn reflects on gene editing's evolution and the closure of Tome Biosciences, highlighting the industry's focus on tools over medicines.
https://endpoints.news/as-gene-editing-tools-multiply-the-hunt-for-the-final-technology-continues/
about 1 month ago
1
2
0
Addition Therapeutics raises $106.5M for all-RNA (no DNA required) gene insertion therapies based on retrotransposons, aka 'jumping genes' Its part of a growing trend of gene editing companies looking beyond CRISPR. My story for
@endpts.com
has the details:
endpoints.news/addition-the...
loading . . .
Berkeley startup raises $106.5M for all RNA 'jumping gene' therapies
Addition Therapeutics has raised $106.5 million for a new way to install therapeutic genes in the human genome.
https://endpoints.news/addition-therapeutics-raises-106-5m-for-all-rna-jumping-gene-therapies/
about 2 months ago
0
3
2
Western drugmakers are increasingly turning to Chinese investigator-initiated trials for a cheaper and faster way to test new drugs. âIf theyâre not doing it, theyâre going to lose,â one US CEO told me.
@leileiwu.bsky.social
and I have the story for
@endpts.com
:
endpoints.news/western-gene...
loading . . .
China has a cheap, quick and quiet way to test novel therapies. Western genetic medicine makers want in
IITs have grown increasingly popular among China researchers over the past decade, and have helped Chinaâs fast-growing biotech sector catch up with rivals in the US and Europe. The very leniency that...
https://endpoints.news/western-genetic-medicine-makers-turn-to-chinese-investigator-initiated-trials/
about 2 months ago
0
1
1
Flagship's gene writing startup Tessera Therapeutics strikes $150M partnership with Regeneron for its AATD therapy, which will start clinical trials soon. CRISPR Tx and Prime Medicine are also working on similar therapies for AATD. More details in
@endpts.com
:
endpoints.news/gene-writing...
loading . . .
Gene writing startup Tessera strikes $150M partnership with Regeneron
Regeneron partners with Tessera Therapeutics in $150M deal to develop gene writing therapy for alpha-1 antitrypsin deficiency, expanding its gene editing investments.
https://endpoints.news/gene-writing-startup-tessera-strikes-150m-partnership-with-regeneron/
2 months ago
0
1
0
China biotech Zhongmou Therapeutics has developed an optogenetic gene therapy that uses an engineered alga protein to restore sight, and it hopes the approach could become a âone-size-fits-allâ rival to Roche's Luxturna. Read more in
@endpts.com
:
endpoints.news/chinas-zhong...
loading . . .
China biotech seeks to rewire eye cells to create âone-size-fits-allâ rival to Luxturna
Wuhan-based Zhongmou Therapeutics reports promising results from gene therapy trial for retinitis pigmentosa, with 7 of 9 blind patients showing vision improvement.
https://endpoints.news/chinas-zhongmou-seeks-to-create-a-one-size-fits-all-rival-to-luxturna/
3 months ago
0
1
0
There's been a death in a
#CRISPR
study, something the field has long feared. A man who was recently hospitalized with liver injury a few weeks after receiving Intellia's experimental gene editing therapy died last night. More details in my story for
@endpts.com
endpoints.news/patient-in-i...
loading . . .
Patient in Intellia CRISPR trial dies after being hospitalized with liver injury
Patient in 80s dies after receiving Intellia Therapeutics' CRISPR therapy nex-z for ATTR. Death follows liver injury; exact cause unclear. CEO John Leonard announces trial pause.
https://endpoints.news/patient-in-intellia-crispr-trial-dies-after-being-hospitalized-with-liver-injury/
3 months ago
0
0
1
Arena BioWorks shuts down after investors pull plug on big bold bet to reinvent biotech, founder Stuart Schreiber confirmed to me. He pointed to biotech macro conditions and also investors seeking bigger returns on AI and tech. Details in my story for
@endpts.com
:
endpoints.news/arena-biowor...
loading . . .
Arena BioWorks shuts down after investors pull plug on bold bid to reinvent biotech model
Arena BioWorks, backed by $500M from billionaires, shuts down after less than 2 years. Founder Stuart Schreiber cites biotech market conditions and investors seeking AI opportunities.
https://endpoints.news/arena-bioworks-shuts-down-after-investors-pull-plug-on-bid-to-reinvent-biotech/
3 months ago
0
0
0
Jennifer Doudna's latest startup, Azalea Therapeutics, launched with $82M. It's based on virus like particles developed by CEO Jenny Hamilton and a new CAR-T trick developed by UCSF's Justin Eyquem. Their goal? The ultimate CRISPR-based in vivo CAR-T.
@endpts.com
-
endpoints.news/jennifer-dou...
loading . . .
Jennifer Doudna startup launches with $82M to apply new CRISPR delivery technology to in vivo CAR-T
Nobel laureate Jennifer Doudna's Azalea Therapeutics raises $82M to develop new CRISPR delivery system for in vivo CAR-T cell therapies targeting blood cancers.
https://endpoints.news/jennifer-doudna-startup-azalea-therapeutics-launches-with-82m/
3 months ago
0
6
4
The scientists behind Baby KJâs life-saving CRISPR therapy have a plan to help more patients. Join me and
@drewsnews.bsky.social
at 9:45 for a conversation with UPenn's Kiran Musunuru and CHOP's Rebecca Ahrens-Nicklas to learn more!
@endpts.com
endpoints.news/post-hoc-liv...
loading . . .
Watch at 9:45 a.m.: Meet the scientists behind Baby KJâs life-saving CRISPR therapy
U Penn's Musunuru and CHOP's Ahrens-Nicklas discuss plans to expand Baby KJ's custom CRISPR therapy for rare genetic diseases into an FDA-approved treatment.
https://endpoints.news/post-hoc-live-meet-the-scientists-behind-baby-kjs-life-saving-crispr-therapy/
3 months ago
1
1
1
DNA-chopping enzyme that breaks up NETs (neutrophil extracellular traps) may offer new way to fight autoimmune disease, early data from
#Neutrolis
suggest. The company has raised $50M from Morningside. Read more in my latest exclusive for
@endpts.com
.
#ACR2025
endpoints.news/dna-chopping...
loading . . .
Exclusive: Breaking up immune webs called NETs may offer new way to treat autoimmune disease, early data suggest
Neutrolis tests enzyme therapy targeting neutrophil extracellular traps (NETs) in Phase 1 trial, showing promise for autoimmune diseases. Drug cleared symptoms in teen with DNASE1L3 deficiency.
https://endpoints.news/dna-chopping-enzyme-that-breaks-up-nets-may-offer-new-way-to-fight-autoimmune-disease-early-data-from-neutrolis-suggest/
3 months ago
0
1
0
Causeway Therapeutics had developed a synthetic
#microRNA
therapy that it hopes will heal injured tendons. The company shared its Phase 2 results with me and its plans to raise a large series A for bigger trials. Read more in my latest story for
@endpts.com
-
endpoints.news/microrna-sta...
loading . . .
Exclusive: Scottish microRNA startup claims signs of success in Phase 2 tendinopathy study
Causeway Therapeutics' microRNA drug for tennis elbow missed primary endpoint in Phase 2, but showed promise in properly injected patients. Plans Phase 3 amid $150M+ fundraising.
https://endpoints.news/microrna-startup-causeway-targets-raise-after-results-of-tendinopathy-study/
4 months ago
0
2
1
Halda Therapeutics has made small molecule drugs called RIPTACs that inhibit an essential protein cells need to live, but only in the presence of a second protein that is primarily found in cancer cells. My story for
@endpts.com
on Halda's first clinical data:
endpoints.news/halda-reveal...
loading . . .
Halda's first clinical test of RIPTAC drugs suggests a safer way to kill cancer
Halda Therapeutics reports promising data for HLD-0915 in prostate cancer trial, with 59% of patients showing PSA reduction of 50%+ after two treatment cycles.
https://endpoints.news/halda-reveals-first-clinical-data-of-riptac-drug-in-prostate-cancer/
4 months ago
0
1
0
Remix Therapeutics has revealed the first clinical data of its "mRNA degrader," a small molecule drug that forces the inclusion of a 'kill switch' into mRNA, leading to its destruction. Its first drug targets the undruggable oncogene MYB. Read more in
@endpts.com
:
endpoints.news/remix-reveal...
loading . . .
Remix Therapeutics reveals first signs of tumor shrinkage with its small molecule mRNA degrader
Remix Therapeutics, which is developing a new way to shut down the expression of cancer-causing genes, has seen the first signs of success in a rare salivary gland cancer.
https://endpoints.news/remix-reveals-first-signs-of-tumor-shrinkage-with-small-molecule-mrna-degrader/
4 months ago
0
1
0
Arcturus announces mixed results of its inhaled
#mRNA
therapy designed to produce CFTR protein in cystic fibrosis patients. And the FDA is asking for more data before reviewing its
#Covid-19
vaccine for approval. My story for
@endpts.com
has the details:
endpoints.news/arcturus-ann...
loading . . .
Arcturusâ stock halved after mixed results of mRNA cystic fibrosis therapy, Covid-19 vaccine delay
The biotech's ambitious attempt to restore the critical protein that is broken or missing in people with cystic fibrosis has yielded mixed results in an ongoing Phase 2 study.
https://endpoints.news/arcturus-announces-mixed-results-of-mrna-cystic-fibrosis-therapy-covid-19-vaccine-delay/
4 months ago
0
1
0
Starna Therapeutics, a Chinese biotech startup founded by mRNA and LNP scientists, has raised a $44M series B to advance its in vivo CAR-T programs after promising, albeit early, results in lupus and cancer patients. Read more in my exclusive story for
@endpts.com
:
endpoints.news/starna-thera...
loading . . .
Exclusive: China biotech raises $44M to advance in vivo CAR-T programs after early clinical data
Chinese biotech Starna Therapeutics reports early success in clinical tests of in vivo CAR-T therapy, eliminating B cells in lupus and lymphoma patients, raising $44M Series B from LYFE Capital and ot...
https://endpoints.news/starna-therapeutics-raises-44m-to-advance-in-vivo-car-t-programs-after-early-clinical-data/
4 months ago
0
0
0
#CRISPR
Therapeutics recently debuted a new gene editing tool called SyNTase editing that it described as 'a significant advance' over prime editing. Prime Medicine disagrees. My latest story for
@endpts.com
digs into the details:
endpoints.news/crispr-thera...
loading . . .
CRISPR Therapeutics says its new gene editing tool is 'a significant advance' over prime editing. Prime Medicine disagrees
CRISPR Therapeutics unveils SyNTase editor tool, plans AATD trial for 2026. Prime Medicine disputes novelty, suggesting similarities to their prime editing tech. Licensing talks reported.
https://endpoints.news/crispr-therapeutics-says-its-new-gene-editing-tool-is-a-significant-advance-over-prime-editing-prime-medicine-disagrees/
4 months ago
0
1
0
British startup Genomics has spent over a decade amassing a human genotype-phenotype database from over 25,000 GWAS studies. Now it is launching a new product to get that data, and software to analyze it, into the hands of drug developers. My story for
@endpts.com
:
endpoints.news/british-star...
loading . . .
British startup Genomics launches business to help drug developers
Oxford spinout Genomics launches Mystra, an AI tool for drug development, using vast genetic database. CEO Peter Donnelly courts pharma leaders from Eli Lilly, Novartis, Roche & Takeda.
https://endpoints.news/british-startup-genomics-launches-business-to-help-drug-developers/
4 months ago
0
2
0
Exclusive for
@endpts.com
: Lipid nanoparticle startup Liberate Bio has emerged with $31M in seed funding from Khosla Ventures and plans to test in vivo cell therapies targeting macrophages and monocytes in the clinic in 2026.
endpoints.news/exclusive-li...
loading . . .
Exclusive: Lipid nanoparticle startup emerges with $31M from Khosla for in vivo cell therapies
Liberate Bio raises $31M seed funding from Khosla Ventures, developing in vivo cell therapy using monocytes and macrophages to fight cancer and other diseases.
https://endpoints.news/exclusive-lipid-nanoparticle-startup-emerges-with-31m-from-khosla-for-in-vivo-cell-therapies/
4 months ago
0
1
0
The Yale spinout Bexorg has raised a $23M series A for its cutting-edge and unconventional approch to preclinical research: testing drugs on ârebootedâ human brains from organ donors. My story for
@endpts.com
has the details:
endpoints.news/bexorg-raise...
loading . . .
Yale spinout raises $23M to test drugs on ârebootedâ human brains from organ donors
Bexorg has collected $23 million in a Series A raise to scale up its human brain experiments, bringing its total funding to $42.5 million, the startup announced Wednesday.
https://endpoints.news/bexorg-raises-23m-to-test-drugs-on-rebooted-human-brains-from-organ-donors/
4 months ago
1
2
1
#ESGCT2025
: A woman who was previously ineligible for
@genethonfr.bsky.social
's CriglerâNajjar syndrome gene therapy due to pre-existing immunity to AAV8 got the treatment after Hansa Bio's antibody-chopping drug imlifidase cleared the way. Read more in
@endpts.com
:
endpoints.news/new-study-su...
loading . . .
Person previously ineligible for gene therapy granted treatment after antibody-chopping drug clears the way
Study shows Hansa's Idefirix helps deliver Genethon's AAV8 gene therapy GNT003 in previously ineligible Crigler-Najjar patient by clearing antibodies, reports Do Cao at ESGCT.
https://endpoints.news/new-study-suggests-patients-with-anti-aav-antibodies-may-still-receive-gene-therapy/
4 months ago
0
4
2
At
#ESGCT2025
, Mammoth Bio presented the first monkey data of its lead program, a gene editing therapy that uses its small Cas-Phi enzyme to target APOC3 for triglyceride reduction. A clinical trial is planed for the second half 2026. More in my story for
@endpts.com
:
endpoints.news/mammoth-bios...
loading . . .
Mammoth Biosciences is getting closer to finding out if its big bet on tiny CRISPR enzymes will pay off
Mammoth Biosciences reveals monkey data for CRISPR therapy targeting APOC3 gene to lower triglycerides, with CEO Trevor Martin planning clinical trials in 2026.
https://endpoints.news/mammoth-biosciences-plans-first-trial-of-triglyceride-lowering-gene-editing-therapy/
4 months ago
0
1
0
At
#ESGCT2025
, Seppo YlÀ-Herttuala from the University of Eastern Finland reported success in Phase 2b study of a gene therapy that uses a surgical technique to inject adenoviruses containing the VEGF-D gene into ischemic heart tissue. My story for
@endpts.com
:
endpoints.news/finnish-rese...
loading . . .
Finnish researchers report success in mid-stage study of heart disease gene therapy
Researchers from the University of Eastern Finland said a gene therapy for people with refractory angina, a form of chronic chest pain that persists despite treatment, was successful in a Phase 2b stu...
https://endpoints.news/finnish-researchers-report-success-in-mid-stage-study-of-heart-disease-gene-therapy/
4 months ago
0
2
0
At
#ESGCT2025
, the scientists behind Baby KJâs custom
#CRISPR
gene editing therapy said they are planning a clinical trial to help more children and turn the one-off drug into an approvable, repeatable procedure. My story for
@endpts.com
has more details. -
endpoints.news/qa-scientist...
loading . . .
Q&A: The scientists behind Baby KJâs custom CRISPR drug are planning a trial to help more children
Scientists led by Kiran Musunuru plan clinical trial for custom gene editing therapies, following success with
https://endpoints.news/qa-scientists-behind-baby-kjs-custom-crispr-drug-are-planning-to-help-more-children/
4 months ago
0
3
0
Arbor Biotechnologies has partnered with Chiesi Group in
#CRISPR
gene editing deal worth up to $2 billion, just 10 weeks after announcing it had dosed the first patient in its PH1 trial. Next up for Arbor: a trio of ALS therapies. Read more in
@endpts.com
-
endpoints.news/arbor-partne...
loading . . .
Arbor partners with Chiesi Group in gene editing deal with potential $2B future payments
Chiesi Group partners with Arbor Biotechnologies in CRISPR deal worth up to $2B for PH1 therapy and rare liver diseases, following first patient dosing in clinical trial.
https://endpoints.news/arbor-partners-with-chiesi-group-in-gene-editing-deal/
4 months ago
0
1
0
I am heading to Spain next week to cover the
#ESGCT2025
meeting for
@endpts.com
. If you're presenting new cell therapy, gene therapy, gene editing or RNA therapy research at the meeting, or just want to meet, reach out!
4 months ago
1
1
1
The French biotech EG 427 has made a gene therpay based on a herpesvirus vector that delivers a botulinum toxin to sensory neurons to reduce urinary incontinence by 88% in spinal cord injury patients. More details on the data and science in my exclusive for @endpts -
endpoints.news/exclusive-fr...
loading . . .
Exclusive: French startup's gene therapy dramatically reduces urinary incontinence in spinal cord injury patients
EG 427's gene therapy shows 88% reduction in urinary incontinence for spinal cord injury patients at 12 weeks, using herpesvirus vector to deliver botulinum toxin F to bladder.
https://endpoints.news/exclusive-french-startups-gene-therapy-dramatically-reduces-urinary-incontinence-in-spinal-cord-injury-patients/
4 months ago
0
2
1
In 2023, Biogen said it would deprioritize its early stage gene therapy research, but a small team of scientists continued working on next-gen AAV capsids. Now Biogen has cut its remaining AAV work. Read more in my exclusive for
@endpts.com
-
endpoints.news/biogen-calls...
loading . . .
Exclusive: Biogen calls it quits on AAV gene therapy, again
Biogen is ending its gene therapy work that relies on adeno-associated viruses, or AAVs, the company confirmed to Endpoints News, making it the latest pharma to walk away from the viral-based delivery...
https://endpoints.news/biogen-calls-it-quits-on-aav-gene-therapy-again/
5 months ago
0
1
0
Feng Zhang's startup Aera Therapeutics has announced an in vivo CAR-T therapy for autoimmune disease as its lead program, and plans to be in clinical trials in mid-2026. Read more about that program, and two more at Aera, in my exclusive for
@endpts.com
-
endpoints.news/aera-therape...
loading . . .
Exclusive: Aera Therapeutics jumps into in vivo CAR-T race with trial planned for 2026
Aera Therapeutics is the latest company hoping that a simple infusion can reprogram the immune system to wipe out errant cells responsible for autoimmune disease. It's planning on testing the in vivo ...
https://endpoints.news/aera-therapeutics-jumps-into-in-vivo-car-t-race-with-trial-planned-for-2026/
5 months ago
0
1
0
One of my favorite rituals at @endpts is picking our annual list of the most promising startups pushing science and medicine forward. Hundreds are nominated, we seriously debate 40-50 of them, and we whittle it down to the Endpoints 11. The list is out!
endpoints.news/the-2025-win...
loading . . .
The Endpoints 11 list: Meet the most exciting biotech startups of 2025
Announcing the 2025 Endpoints 11 winners â the most exciting, high-risk, high-reward biotech startups of the year.
https://endpoints.news/the-2025-winners-of-the-endpoints-11-biotechs-most-exciting-startups/
5 months ago
1
2
0
I spoke with
#LaskerAward
winner Michael Welsh from the University of Iowa about how he helped unravel the molecular mechanisms of
#CysticFibrosis
that laid the foundation for Vertex's life-saving drugs for the once fatal disease. Read the interview on
@endpts.com
:
endpoints.news/a-conversati...
loading . . .
Q&A: Lasker Award winner Michael Welsh on the science that led to life-saving cystic fibrosis drugs
Scientists Welsh, GonzĂĄlez, and Negulescu win Lasker Award for cystic fibrosis research, including Welsh's molecular insights and Vertex's Trikafta drug development.
https://endpoints.news/a-conversation-with-lasker-award-winner-michael-welsh-on-life-saving-cystic-fibrosis-drugs/
5 months ago
0
0
0
Chinese
#CRISPR
company YolTech Therapeutics has raised a $45M series B as it plans for its first Phase 3 study in ATTR, the same genetic disease that US-based Intellia recently began a pair of Phase 3 studies in. Read more in my exclusive for
@endpts.com
:
endpoints.news/chinese-cris...
loading . . .
Exclusive: Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study
YolTech Therapeutics raises $44.5M Series B for CRISPR therapies, led by AstraZeneca-CICC fund. Company has 4 therapies in clinical trials, plans Phase 3 for ATTR treatment.
https://endpoints.news/chinese-crispr-company-yoltech-raises-45m-as-it-plans-for-first-phase-3-study/
5 months ago
0
1
0
China biotech Epigenic Therapeutics raises $60M to test
#CRISPR
#epigenetic
therapies for HBV in Phase 1/2 trial, competing with US startups nChroma and Tune. Read more from my exclusive interview with Epigenic CEO Bob Zhang in my story for
@endpts.com
endpoints.news/china-biotec...
loading . . .
China biotech Epigenic raises $60M to test CRISPR epigenetic therapies
Epigenic Therapeutics raises $60M Series B for CRISPR-based hepatitis B therapy, with CEO Bob Zhang leading clinical trials in New Zealand, China and US through 2027.
https://endpoints.news/china-biotech-epigenic-raises-60m-to-test-crispr-epigenetic-therapies/
5 months ago
0
2
0
Neuropsych startup Sensorium, founded by Mass General and Harvard scientists, has raised $25M for a Phase 1 study of a new plant-derived drug for anxiety. CEO Jacob Hooker told me about the drug's mechanism for the first time in my exclusive story for
@endpts.com
:
endpoints.news/sensorium-ra...
loading . . .
Exclusive: Sensorium raises $25M to test succulent-derived drug for anxiety
Sensorium, a startup founded by scientists from Mass General and Harvard in 2021 to look for new brain drugs from plants and fungi, has raised a $25 million series A extension, the company told Endpoi...
https://endpoints.news/sensorium-raises-25m-for-clinical-tests-of-succulent-derived-drug-for-anxiety/
6 months ago
0
0
0
Gameto, a startup looking to disrupt the in vitro fertilization industry with stem cell technology from George Church's lab, has raised $44 million in Series C financing for its Phase 3 study. My story for
@endpts.com
has the details:
endpoints.news/fertility-st...
loading . . .
Fertility startup Gameto raises $44M to fund Phase 3 study of stem cell IVF therapy
The new funding will allow Gameto to finish a Phase 3 study of its therapy in 500 people looking to conceive via in vitro fertilization.
https://endpoints.news/fertility-startup-gameto-raises-44m-to-fund-phase-3-study-of-stem-cell-ivf-therapy/
6 months ago
0
1
1
After promising proof of concept data from a Phase 1 study earlier this year, Strand Therapeutics has raised $153 million series B funding to test its
#mRNA
cancer therapies encoding the potent immune-stimulating protein IL-12. Read more in Endpoints News:
endpoints.news/strand-thera...
loading . . .
Strand Therapeutics nabs $153M to test mRNA cancer therapies
Strand Therapeutics, a startup based on research from MIT, has managed to pull off one of the largest raises for an mRNA-focused biotech in recent years.
https://endpoints.news/strand-therapeutics-nabs-153m-to-test-mrna-cancer-therapies/
6 months ago
0
1
0
The session at
#AAIC25
on Roche's next-gen
#Alzheimers
drug
#trontinemab
was jam packed and despite one patient's death, the excitement for this drug was palpable. Read more about the dramatic amyloid reduction and surprisingly low ARIA in
@endpts.com
-
endpoints.news/roche-double...
loading . . .
Roche doubles down on its Alzheimer's ambitions as next-gen amyloid-lowering drug excites scientists
Roche revealed the latest cut of data from its closely-watched Phase 1/2 study of trontinemab, an amyloid-targeting antibody designed to latch onto receptors that yank it across the protective blood-b...
https://endpoints.news/roche-doubles-down-on-its-alzheimers-ambitions-as-next-gen-amyloid-lowering-drug-excites-scientists/
7 months ago
0
1
1
Orbital Therapeutics, a circular RNA startup that raised $270M for nex-gen RNA drugs in 2023, revealed its first program and first preclinical data for an in vivo CAR-T cell therapy for autoimmune disease. More details in my story for
@endpts.com
-
endpoints.news/circular-rna...
loading . . .
Exclusive: Circular RNA startup Orbital unveils first monkey data as it enters in vivo CAR-T cell therapy race
Orbital Therapeutics reveals first preclinical data for circular RNA-based in vivo CAR-T therapy for autoimmune diseases, showing B cell elimination in monkeys with two infusions.
https://endpoints.news/circular-rna-startup-orbital-unveils-first-monkey-data-as-it-enters-in-vivo-car-t-cell-therapy-race/
7 months ago
0
3
1
David Bakerâs lab
@uwproteindesign.bsky.social
uses AI to catch natureâs squirmiest proteins, the notoriously undruggable intrinsically disordered proteins. I covered the new methods, which could have implications in cancer, diabetes, pain and more for
@endpts.com
-
endpoints.news/david-bakers...
loading . . .
David Bakerâs lab uses AI to help catch natureâs squirmiest proteins
David Baker reveals AI strategies to develop proteins binding to intrinsically disordered proteins (IDPs), enabling potential drug development for previously
https://endpoints.news/david-bakers-lab-uses-ai-to-help-catch-natures-squirmiest-proteins/
7 months ago
0
1
0
Load more
feeds!
log in